416 related articles for article (PubMed ID: 16861252)
1. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded bispecific antibody comprising of two single-chain antibodies linked to the antibody constant region.
Natsume A; Wakitani M; Yamane-Ohnuki N; Shoji-Hosaka E; Niwa R; Uchida K; Satoh M; Shitara K
J Biochem; 2006 Sep; 140(3):359-68. PubMed ID: 16861252
[TBL] [Abstract][Full Text] [Related]
2. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region.
Natsume A; Wakitani M; Yamane-Ohnuki N; Shoji-Hosaka E; Niwa R; Uchida K; Satoh M; Shitara K
J Immunol Methods; 2005 Nov; 306(1-2):93-103. PubMed ID: 16236307
[TBL] [Abstract][Full Text] [Related]
3. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
[TBL] [Abstract][Full Text] [Related]
4. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides.
Niwa R; Natsume A; Uehara A; Wakitani M; Iida S; Uchida K; Satoh M; Shitara K
J Immunol Methods; 2005 Nov; 306(1-2):151-60. PubMed ID: 16219319
[TBL] [Abstract][Full Text] [Related]
5. Enhanced Fc-dependent cellular cytotoxicity of Fc fusion proteins derived from TNF receptor II and LFA-3 by fucose removal from Asn-linked oligosaccharides.
Shoji-Hosaka E; Kobayashi Y; Wakitani M; Uchida K; Niwa R; Nakamura K; Shitara K
J Biochem; 2006 Dec; 140(6):777-83. PubMed ID: 17038352
[TBL] [Abstract][Full Text] [Related]
6. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism.
Niwa R; Hatanaka S; Shoji-Hosaka E; Sakurada M; Kobayashi Y; Uehara A; Yokoi H; Nakamura K; Shitara K
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6248-55. PubMed ID: 15448014
[TBL] [Abstract][Full Text] [Related]
8. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells.
Asano R; Kawaguchi H; Watanabe Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
J Immunother; 2008 Oct; 31(8):752-61. PubMed ID: 18779744
[TBL] [Abstract][Full Text] [Related]
9. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities.
Natsume A; In M; Takamura H; Nakagawa T; Shimizu Y; Kitajima K; Wakitani M; Ohta S; Satoh M; Shitara K; Niwa R
Cancer Res; 2008 May; 68(10):3863-72. PubMed ID: 18483271
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a novel bispecific antibody that mediates Fcgamma receptor type I-dependent killing of tumor-associated glycoprotein-72-expressing tumor cells.
Russoniello C; Somasundaram C; Schlom J; Deo YM; Keler T
Clin Cancer Res; 1998 Sep; 4(9):2237-43. PubMed ID: 9748144
[TBL] [Abstract][Full Text] [Related]
11. A new format of bispecific antibody: highly efficient heterodimerization, expression and tumor cell lysis.
Xie Z; Guo N; Yu M; Hu M; Shen B
J Immunol Methods; 2005 Jan; 296(1-2):95-101. PubMed ID: 15680154
[TBL] [Abstract][Full Text] [Related]
12. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density.
Niwa R; Sakurada M; Kobayashi Y; Uehara A; Matsushima K; Ueda R; Nakamura K; Shitara K
Clin Cancer Res; 2005 Mar; 11(6):2327-36. PubMed ID: 15788684
[TBL] [Abstract][Full Text] [Related]
13. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa.
Iida S; Misaka H; Inoue M; Shibata M; Nakano R; Yamane-Ohnuki N; Wakitani M; Yano K; Shitara K; Satoh M
Clin Cancer Res; 2006 May; 12(9):2879-87. PubMed ID: 16675584
[TBL] [Abstract][Full Text] [Related]
14. Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1.
Matsumiya S; Yamaguchi Y; Saito J; Nagano M; Sasakawa H; Otaki S; Satoh M; Shitara K; Kato K
J Mol Biol; 2007 May; 368(3):767-79. PubMed ID: 17368483
[TBL] [Abstract][Full Text] [Related]
15. Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity.
Masuda K; Kubota T; Kaneko E; Iida S; Wakitani M; Kobayashi-Natsume Y; Kubota A; Shitara K; Nakamura K
Mol Immunol; 2007 May; 44(12):3122-31. PubMed ID: 17379311
[TBL] [Abstract][Full Text] [Related]
16. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa.
Okazaki A; Shoji-Hosaka E; Nakamura K; Wakitani M; Uchida K; Kakita S; Tsumoto K; Kumagai I; Shitara K
J Mol Biol; 2004 Mar; 336(5):1239-49. PubMed ID: 15037082
[TBL] [Abstract][Full Text] [Related]
17. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity.
Yamane-Ohnuki N; Kinoshita S; Inoue-Urakubo M; Kusunoki M; Iida S; Nakano R; Wakitani M; Niwa R; Sakurada M; Uchida K; Shitara K; Satoh M
Biotechnol Bioeng; 2004 Sep; 87(5):614-22. PubMed ID: 15352059
[TBL] [Abstract][Full Text] [Related]
18. Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity.
Natsume A; Shimizu-Yokoyama Y; Satoh M; Shitara K; Niwa R
Cancer Sci; 2009 Dec; 100(12):2411-8. PubMed ID: 19758394
[TBL] [Abstract][Full Text] [Related]
19. The N-linked oligosaccharide at Fc gamma RIIIa Asn-45: an inhibitory element for high Fc gamma RIIIa binding affinity to IgG glycoforms lacking core fucosylation.
Shibata-Koyama M; Iida S; Okazaki A; Mori K; Kitajima-Miyama K; Saitou S; Kakita S; Kanda Y; Shitara K; Kato K; Satoh M
Glycobiology; 2009 Feb; 19(2):126-34. PubMed ID: 18952826
[TBL] [Abstract][Full Text] [Related]
20. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II.
Ferrara C; Brünker P; Suter T; Moser S; Püntener U; Umaña P
Biotechnol Bioeng; 2006 Apr; 93(5):851-61. PubMed ID: 16435400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
